Takeda reports Q3 core EPS 428 yen vs. 443 yen last year

Reports Q3 revenue 3.41B yen vs. 3.53B yen last year. Takeda (TAK) chief financial officer, Milano Furuta, commented: “While we manage the impact of Vyvanse generics, we are implementing disciplined cost management and improving operational efficiency and therefore expect to achieve the previously disclosed Management Guidance for Core Operating Profit. FY2025 remains a truly pivotal year for Takeda as we are in a phase of preparing for significant new product launches. Looking ahead, with multiple innovative launches and a robust late-stage pipeline, Takeda is positioned to bring life-transforming medicines that improve patient lives and deliver long-term shareholder value.”